Olivier Tabary
Paris, 75012, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Ano1 Antisense Therapy Improves Enamel Properties in Molars but not Amelogenesis in a Murine Model of Cystic Fibrosis.
Journal: Calcified tissue international
Published: October 04, 2025
Restoring chloride efflux in cystic fibrosis with TMEM16a antisense oligonucleotides.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: February 05, 2025
Multicentric investigations of the role in the disease severity of accelerated phospholipid changes in COVID-19 patient airway.
Journal: Microbes and infection
Published: May 12, 2023
Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?
Journal: Drugs
Published: October 27, 2022
TMEM16A/ANO1: Current Strategies and Novel Drug Approaches for Cystic Fibrosis.
Journal: Cells
Published: October 04, 2021
Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies.
Journal: Frontiers in pharmacology
Published: April 30, 2020
miR-636: A Newly-Identified Actor for the Regulation of Pulmonary Inflammation in Cystic Fibrosis.
Journal: Frontiers in immunology
Published: August 20, 2019
Emerging microRNA Therapeutic Approaches for Cystic Fibrosis.
Journal: Frontiers in pharmacology
Published: July 13, 2018
Opposite Expression of Hepatic and Pulmonary Corticosteroid-Binding Globulin in Cystic Fibrosis Patients.
Journal: Frontiers in pharmacology
Published: March 23, 2018
Small RNA and transcriptome sequencing reveal the role of miR-199a-3p in inflammatory processes in cystic fibrosis airways.
Journal: The Journal of pathology
Published: October 31, 2017
MicroRNA-9 downregulates the ANO1 chloride channel and contributes to cystic fibrosis lung pathology.
Journal: Nature communications
Published: August 17, 2016
Last Updated: 09/26/2026